Show simple item record

dc.contributor.authorMarschall, Andrea L J
dc.contributor.authorDübel, Stefan
dc.date.accessioned2016-10-07T13:15:15Z
dc.date.available2016-10-07T13:15:15Z
dc.date.issued2016
dc.identifier.citationAntibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm? 2016, 14:304-8 Comput Struct Biotechnol Jen
dc.identifier.issn2001-0370
dc.identifier.pmid27570612
dc.identifier.doi10.1016/j.csbj.2016.07.003
dc.identifier.urihttp://hdl.handle.net/10033/620543
dc.description.abstractChallenges posed by complex diseases such as cancer, chronic viral infections, neurodegenerative disorders and many others have forced researchers to think beyond classic small molecule drugs, exploring new therapeutic strategies such as therapy with RNAi, CRISPR/Cas9 or antibody therapies as single or as combination therapies with existing drugs. While classic antibody therapies based on parenteral application can only reach extracellular targets, intracellular application of antibodies could provide specific advantages but is so far little recognized in translational research. Intrabodies allow high specificity and targeting of splice variants or post translational modifications. At the same time off target effects can be minimized by thorough biochemical characterization. Knockdown of cellular proteins by intrabodies has been reported for a significant number of disease-relevant targets, including ErbB-2, EGFR, VEGFR-2, Metalloproteinase MMP2 and MMP9, β-amyloid protein, α-synuclein, HIV gp120, HCV core and many others. This review outlines the recent advances in ER intrabody technology and their potential use in therapy.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleAntibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?en
dc.typeArticleen
dc.contributor.departmentBRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56, 38106 Braunschweig, Germany.en
dc.identifier.journalComputational and structural biotechnology journalen
refterms.dateFOA2018-06-12T17:54:07Z
html.description.abstractChallenges posed by complex diseases such as cancer, chronic viral infections, neurodegenerative disorders and many others have forced researchers to think beyond classic small molecule drugs, exploring new therapeutic strategies such as therapy with RNAi, CRISPR/Cas9 or antibody therapies as single or as combination therapies with existing drugs. While classic antibody therapies based on parenteral application can only reach extracellular targets, intracellular application of antibodies could provide specific advantages but is so far little recognized in translational research. Intrabodies allow high specificity and targeting of splice variants or post translational modifications. At the same time off target effects can be minimized by thorough biochemical characterization. Knockdown of cellular proteins by intrabodies has been reported for a significant number of disease-relevant targets, including ErbB-2, EGFR, VEGFR-2, Metalloproteinase MMP2 and MMP9, β-amyloid protein, α-synuclein, HIV gp120, HCV core and many others. This review outlines the recent advances in ER intrabody technology and their potential use in therapy.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Marshall and Dübel.pdf
Size:
529.0Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/